Posted by Michael Wonder on 06 Sep 2024
Sun Pharma and Moebius Medical announce fast track designation granted for MM-II for the treatment of osteoarthritis knee pain
6 September 2024 - Sun Pharma and Moebius Medical announced that the US FDA has granted fast track designation to MM-II (large liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain.
Planning for confirmatory Phase 3 clinical trials for MMII is underway.
